← All indications
Hypertension, Portal
Abnormal increase of resistance to blood flow within the hepatic PORTAL SYSTEM, frequently seen in LIVER CIRRHOSIS and conditions with obstruction of the PORTAL VEIN.
Subtype terms (3)
More specific conditions that are subtypes of Hypertension, Portal in the MeSH hierarchy.
- Esophageal and Gastric Varices
72 drugs (47 approved, 25 experimental)
- Idiopathic Noncirrhotic Portal Hypertension
- Sinistral Portal Hypertension
Drugs by status
Phase 4 trials (24)
Phase 3 trials (9)
Phase 2 trials (22)
Phase 1 trials (1)
Other trials (21)
- 131i-lipiodol
- carbon dioxide
- clavulanate
- cyanoacrylate
- ivabradine
- indocyanine green
- amoxicillin
- norfloxacin
- polidocanol
- autologous microbiome
- bifidobacterium infantis
- bifidobacterium breve
- bifidobacterium longum
- lactobacillus plantarum
- fentanyl
- propanolol
- chickpea
- Streptococcus thermophilus
- perflutren protein-type a microspheres
- neomycin
- erythromycin
Organizations
Organization Involved with Phase 4 Indications (35)
- Ferozsons Laboratories Ltd.
- Norgine
- Huazhong University of Science and Technology
- Qilu Hospital of Shandong University
- Maastricht University
- Katholieke Universiteit Leuven
- King Faisal University
- Linyi People's Hospital
- Radboud University
- Qingdao University
- Shanghai University of Traditional Chinese Medicine
- Tanta University
- University of Groningen
- University of South Florida
- Yangzhou University
- Aga Khan University
- Fudan University
- University of Copenhagen
- University of Naples Frederico II
- Shandong University
- University of Vienna
- Leiden University
- University of Amsterdam
- Jiao Tong University
- Shanghai University
- Southern Medical University
- Tampa General Medical Group
- Second Military Medical University
- University of Barcelona
- Erasmus University Rotterdam
- +5 more
Organization Involved with Phase 3 Indications (33)
- Celgene
- Debiopharm
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- University of London
- Cornell University
- Harvard University
- Dow University of Health Sciences
- Govind Ballabh Pant Institute of Postgraduate Medical Education and Research
- Indiana University
- Johns Hopkins University
- Northwestern University
- Rio de Janeiro State University
- Rutgers University
- Tufts University
- University of Kentucky
- University of Padua
- University of Rochester
- University of Athens
- Virginia Commonwealth University
- Yale University
- Yonsei University
- Mayo Clinic
- University of California, San Diego
- University of Colorado, Denver
- Medical University of South Carolina
- Federal University of Rio de Janeiro
- Mission Health, North Carolina
- University of Alabama, Birmingham
- Alabama Liver & Digestive Specialists Research Center
- Washington University in St. Louis
- +3 more
Organization Involved with Phase 2 Indications (16)
- Onyx
- Forest Laboratories
- Gilead Sciences
- Novartis
- Cumberland Pharmaceuticals
- Galectin Therapeutics Inc.
- Sucampo
- National Center for Research Resources (NCRR)
- United States Army
- Centro de Investigación Biomédica en Red (CIBER)
- NHS Lothian
- University of Edinburgh
- University of Alberta
- Conatus Pharmaceuticals
- The University of Texas, Dallas
- Noorik Biopharmaceuticals AG
Organization Involved with Phase 1 Indications (2)
Organization Involved with Other Experimental Indications (17)
- Roche
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- LanZhou University
- Monash University
- National Cheng Kung University
- Postgraduate Institute of Medical Education and Research
- Sichuan University
- Capital Medical University
- Institute of Liver and Biliary Sciences, India
- Xiamen University
- The Alfred Hospital
- Xingtai People's Hospital
- Pomeranian Medical University
- Faculdade de Medicina de Botucatu
- Sao Paulo State University
- Department of Veteran Affairs
- GRAPE KING